Aardvark Therapeutics, Inc. (AARD) Stock Price & Analysis
Aardvark Therapeutics, Inc. (AARD) fell 0.28% to USD 3.58 as of June 10, 2026 at 07:46 UTC, according to Nexqual real-time market data.
AARD last closed at USD 3.59; the session ranged USD 3.46–3.73 on volume of 106,258 shares. Market capitalization is $78.10M, with a 52-week range of USD 3.35–17.94 (NMS). Source: Nexqual, June 10, 2026 at 07:46 UTC.
Key Statistics (as of June 10, 2026 at 07:46 UTC)
| Price | USD 3.58 |
|---|---|
| Change | ▼ 0.28% (down) |
| Previous Close | USD 3.59 |
| Open | USD 3.58 |
| Day Range | USD 3.46 – 3.73 |
| 52-Week Range | USD 3.35 – 17.94 |
| Volume | 106,258 shares |
| Market Cap | $78.10M |
| Exchange | NMS |
Technical Analysis (AARD)
Nexqual's technical model rates AARD "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.39 (neutral) |
| vs SMA50 | Below (USD 4.73) |
| MACD | -0.42 (negative) |
Analyst Ratings (AARD)
Wall Street analysts rate AARD "Buy" based on 9 analysts, with a mean price target of USD 15.44 (range USD 3–45), per Nexqual as of June 10, 2026 at 07:46 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 15.44 |
| High Target | USD 45 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 6 / 4 / 2 |
Earnings (AARD)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -0.87 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.99 vs est -0.91 ▼ miss |
| 2025-12-31 | USD -0.81 vs est -0.83 ▲ beat |
| 2025-09-30 | USD -0.75 vs est -0.8 ▲ beat |
| 2025-06-30 | USD -0.66 vs est -0.6 ▼ miss |
Source: Nexqual, June 10, 2026 at 07:46 UTC.
Financials & Fundamentals (AARD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -58.79% |
| Debt / Equity | 0.39 |
| Current Ratio | 8.06 |
| Total Cash | $91.20M |
| Total Debt | $336,000 |
| Free Cash Flow | $-34.44M |
Source: Nexqual, June 10, 2026 at 07:46 UTC.
Financial Health Score (AARD)
Nexqual rates Aardvark Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $91M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$62M |
| Efficiency | Critical — ROE -59%, ROA -36.5% |
Ownership (AARD)
| Insider Ownership | +16.15% |
|---|---|
| Institutional Ownership | +56.42% |
| Shares Outstanding | 21.82M |
| Float | 10.91M |
| Short % of Float | +6.85% |
Source: Nexqual, June 10, 2026 at 07:46 UTC.
Leadership (AARD)
Aardvark Therapeutics, Inc. is led by Tien-Li Lee (age 50), CEO, Secretary & Director, per Nexqual as of June 10, 2026 at 07:46 UTC.
| CEO, Secretary & Director | Tien-Li Lee (age 50) |
|---|---|
| CFO & COO | Nelson B. Sun (age 48) |
| Chief Scientific Officer | Timothy J. Kieffer (age 58) |
| Executive Vice President of Medical Affairs | Dvorit Samid |
Major Backers & Investors (AARD)
Notable institutional backers of Aardvark Therapeutics, Inc. include Decheng Capital LLC, Citadel, Laurion Capital Management, LP, according to Nexqual as of June 10, 2026 at 07:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Decheng Capital LLC | 17.96% |
| Citadel | 5.7% |
| Laurion Capital Management, LP | 4.74% |
| Tetragon Partners GP Ltd. | 1.45% |
| Adage Capital Partners GP L.L.C. | 1.38% |
| Fidelity | 0.9% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.92% |
| Vanguard Group | 5.3% |
| Geode Capital | 1.42% |
| State Street | 0.91% |
Source: Nexqual, June 10, 2026 at 07:46 UTC.
From Aardvark Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | USD 23.93 | ▼ 1.4% |
| SION | Sionna Therapeutics, Inc. | USD 33.69 | ▼ 4.75% |
| BCAX | Bicara Therapeutics Inc. | USD 20.56 | ▲ 2.8% |
| UPB | Upstream Bio, Inc. | USD 6.69 | ▼ 5.11% |
| MBX | MBX Biosciences, Inc. | USD 29.87 | ▼ 1.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:46 UTC. This page is informational and not investment advice.